Acceptability Lactoserum (Dermacyd Delicata - New Fragrance)

The purpose of this study is to demonstrate the safety of the gynecological formulation in normal and usual usage condition of Dermacyd Femina Delicata.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hygiene

Age range

18 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Sanofi-aventis

São Paulo, Brazil

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Integral skin in the tested region

Exclusion criteria

Pregnancy or breastfeeding women
Use of Anti-inflammatory or immune-suppression drugs
Topical medication use at the tested region
Active cutaneous gynaecological disease which may interfere in study results
Personal history of allergic disease at the area to be treated
Allergic or atopic history

The above information is not intended to contain considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

lactoserum

Drug

Primary outcomes

Clinical and local tolerability

Time frame: 21 days
Adverse events and their association with the treatment.

Time frame: 21 days

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

Safety Dermatological Evaluation of the Acceptability With Gynecological Follow up for Dermacyd Femina Delicata

Important dates

Study start: 2007
First posted: Jul 9, 2007
Registry last updated: May 20, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed